Literature DB >> 11216206

Reason for hope: the advent of disease-modifying therapies in multiple sclerosis.

P W O'Connor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11216206      PMCID： PMC1232237     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

2.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

3.  Intrathecal interferon reduces exacerbations of multiple sclerosis.

Authors:  L Jacobs; J O'Malley; A Freeman; R Ekes
Journal:  Science       Date:  1981-11-27       Impact factor: 47.728
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.